North Rock Partners, LLC Bristol Myers Squibb CO Transaction History

North Rock Partners, LLC

$2.97 Billion
Q1 2025

A detailed history of North Rock Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, North Rock Partners, LLC holds 28,735 shares of BMY stock, worth $1.35 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

28,735

Previous 26,759 7.38%

Holding current value

$1.35 Million

Previous $1.51 Million 15.8%

% of portfolio

0.06%

Previous 0.05%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$53.9 - $63.11 $106,506 - $124,705	1,976 Added 7.38%	28,735 $1.75 Million
Q4 2024 Apr 22, 2025	BUY	$51.92 - $59.94 $30,840 - $35,604	594 Added 2.27%	26,759 $1.51 Million
Q4 2024 Feb 14, 2025	BUY	$51.92 - $59.94 $917,530 - $1.06 Million	17,672 Added 192.78%	26,839 $1.52 Million
Q3 2024 Apr 22, 2025	BUY	$39.66 - $51.75 $362,571 - $473,098	9,142 Added 53.7%	26,165 $1.35 Million
Q3 2024 Oct 30, 2024	BUY	$39.66 - $51.75 $47,710 - $62,255	1,203 Added 15.11%	9,167 $474,000
Q2 2024 Apr 22, 2025	SELL	$40.25 - $52.99 $395,094 - $520,149	-9,816 Reduced 36.57%	17,023 $706,000
Q2 2024 Aug 06, 2024	BUY	$40.25 - $52.99 $87,825 - $115,624	2,182 Added 37.74%	7,964 $330,000
Q1 2024 Apr 22, 2025	BUY	$47.98 - $54.4 $59,974 - $68,000	1,250 Added 8.75%	15,537 $842,000
Q1 2024 May 07, 2024	SELL	$47.98 - $54.4 $137,078 - $155,420	-2,857 Reduced 33.07%	5,782 $313,000
Q4 2023 Apr 22, 2025	SELL	$48.48 - $57.85 $608,520 - $726,133	-12,552 Reduced 46.77%	14,287 $733,000
Q4 2023 Feb 08, 2024	SELL	$48.48 - $57.85 $90,512 - $108,005	-1,867 Reduced 17.77%	8,639 $443,000
Q3 2023 Oct 24, 2023	BUY	$57.89 - $64.73 $36,123 - $40,391	624 Added 6.31%	10,506 $609,000
Q2 2023 Aug 02, 2023	BUY	$63.71 - $70.74 $42,303 - $46,971	664 Added 7.2%	9,882 $631,000
Q1 2023 May 03, 2023	SELL	$65.71 - $74.53 $155,075 - $175,890	-2,360 Reduced 20.38%	9,218 $638,000
Q4 2022 Feb 01, 2023	BUY	$68.48 - $81.09 $236,872 - $280,490	3,459 Added 42.6%	11,578 $832,000
Q3 2022 Nov 02, 2022	SELL	$0.13 - $76.84 $135 - $80,297	-1,045 Reduced 11.4%	8,119 $577,000
Q2 2022 Aug 04, 2022	SELL	$72.62 - $79.98 $16,194 - $17,835	-223 Reduced 2.38%	9,164 $706,000
Q1 2022 May 05, 2022	BUY	$61.48 - $73.72 $146,260 - $175,379	2,379 Added 33.95%	9,387 $686,000
Q4 2021 Feb 07, 2022	BUY	$53.63 - $62.52 $78,299 - $91,279	1,460 Added 26.32%	7,008 $437,000
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $33,786 - $39,576	571 Added 11.47%	5,548 $328,000
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $15,539 - $16,922	251 Added 5.31%	4,977 $333,000
Q1 2021 May 11, 2021	SELL	$59.34 - $66.74 $95,181 - $107,050	-1,604 Reduced 25.34%	4,726 $298,000
Q4 2020 Feb 08, 2021	SELL	$57.74 - $65.43 $56,642 - $64,186	-981 Reduced 13.42%	6,330 $393,000
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $60,646 - $67,203	-1,056 Reduced 12.62%	7,311 $441,000
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $325,082 - $380,053	-5,930 Reduced 41.48%	8,367 $492,000
Q2 2020 Aug 11, 2020	BUY	$54.82 - $64.09 $347,778 - $406,586	6,344 Added 79.77%	14,297 $492,000
Q1 2020 May 13, 2020	SELL	$46.4 - $67.43 $280,812 - $408,086	-6,052 Reduced 43.21%	7,953 $443,000
Q4 2019 Feb 12, 2020	SELL	$49.21 - $64.19 $12.8 Million - $16.7 Million	-260,232 Reduced 94.89%	14,005 $899,000
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $13.2 Million - $17.3 Million	268,982 Added 5118.59%	274,237 $899,000
Q3 2019 Nov 12, 2019	BUY	$42.77 - $50.71 $224,756 - $266,481	5,255 New	5,255 $266,000
Q1 2019 May 14, 2019	SELL	$45.12 - $53.8 $202,137 - $241,024	-4,480 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $218,444 - $283,270	4,480 New	4,480 $232,000

Others Institutions Holding BMY

# of Institutions

2,806

Shares Held

1.59B

Call Options Held

25.9M

Put Options Held

23.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.6B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of North Rock Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on North Rock Partners, LLC with notifications on news.

Account

North Rock Partners, LLC Bristol Myers Squibb CO Transaction History